blood
vessel
damag
circul
platelet
come
contact
activ
stimuli
trigger
aggreg
enabl
form
hemostat
plug
process
subject
posit
neg
feedback
ensur
platelet
respond
appropri
damag
form
thrombi
total
occlud
vessel
believ
dysregul
neg
feedback
mechan
contribut
increas
risk
thrombosi
associ
diseas
despit
associ
thrombosi
plateletderiv
neg
regul
platelet
activ
rel
poorli
understood
comparison
mediat
platelet
activ
howev
becom
increasingli
appar
mechan
platelet
restrain
activ
divers
equal
complex
mediat
posit
signal
regul
jama
act
gatekeep
must
deactiv
platelet
activ
occur
contrast
regul
contain
itim
activ
follow
stimul
mediat
neg
regul
via
phosphatas
restrain
activ
esam
thought
directli
limit
plateletplatelet
adhes
block
activ
fibrinogen
receptor
integrin
variou
isoform
pkc
express
platelet
elicit
divers
complex
array
inhibitori
effect
includ
receptor
desensitis
mani
platelet
deriv
inhibitor
identifi
yet
fulli
character
question
remain
regard
detail
role
regul
platelet
activ
chapter
describ
plateletderiv
inhibitor
platelet
function
secret
express
within
platelet
provid
inhibit
neg
regul
process
underpin
activ
tabl
platelet
endotheli
cell
adhes
kda
member
immunoglobulin
superfamili
express
sever
haematopoiet
cell
includ
platelet
monocyt
neutrophil
type
cell
endotheli
cell
associ
sever
biolog
process
includ
neg
regul
platelet
activ
newman
contain
amino
acid
extracellular
domain
compos
iglik
domain
mediat
homophil
interact
molecul
also
contain
short
amino
acid
singl
transmembran
span
domain
amino
acid
cytoplasm
domain
includ
itim
sun
et
al
newton
et
al
goyert
et
al
lyon
et
al
express
level
variabl
copi
number
rang
present
cell
surfac
per
platelet
jone
et
al
present
platelet
result
increas
cell
surfac
express
follow
platelet
activ
granul
secret
hidari
et
al
wu
lian
metzelaar
et
al
jone
et
al
believ
activ
homomer
cluster
thai
le
et
al
interact
receptor
also
report
buckley
et
al
cluster
itam
contain
receptor
ligat
use
antibodi
recombin
human
immunoglobulin
chimera
shown
inhibit
gpvi
gpib
gpcrstimul
platelet
aggreg
activ
broad
effect
signal
transduct
includ
reduc
total
tyrosin
phosphoryl
inositol
trisphosph
product
mobilis
granul
secret
underpin
reduct
thrombu
format
cicmil
et
al
jone
et
al
thai
et
al
rathor
et
al
platelet
exhibit
hyperreact
stimul
low
concentr
collagen
crp
collagen
relat
peptid
thrombin
adp
par
receptor
agonist
studi
measur
laserinduc
thrombu
format
cremast
muscl
arteriol
vivo
use
mice
defici
indic
inhibitori
role
regul
thrombu
format
increas
thrombu
size
stabil
observ
falati
et
al
regul
phosphoryl
cytoplasm
tail
tyrosin
residu
within
itim
itsm
immunoreceptor
tyrosinebas
switch
motif
motif
constitut
phosphoryl
low
level
rest
platelet
phosphoryl
increas
follow
antibodi
induc
crosslink
also
respons
sever
platelet
agonist
includ
collagen
convulxin
thrombin
gpib
agonist
suggest
provid
neg
feedback
mechan
control
level
platelet
activ
thrombu
format
jackson
et
al
modderman
et
al
cicmil
et
al
jone
et
al
rathor
et
al
phosphoryl
itim
mediat
activ
src
famili
kinas
fyn
lyn
src
ye
hck
shown
coimmunoprecipit
cao
et
al
cicmil
et
al
phosphoryl
itim
provid
bind
activ
platform
domain
contain
protein
includ
phosphatas
pumphrey
et
al
relou
et
al
henshal
et
al
associ
neg
regul
platelet
activ
follow
activ
gpvi
signal
associ
lat
signalosom
locat
lipid
raft
enrich
phosphoinositid
substrat
contrast
lat
major
molecul
exclud
lipid
raft
follow
crosslink
recruit
associ
relocalis
away
lipid
raft
lat
signalosom
prevent
associ
activ
mora
et
al
recent
mechan
neg
regul
respons
nongpvi
agonist
thrombin
vwf
also
describ
jone
et
al
inhibit
fibrinogen
bind
secret
stimul
thrombin
activ
peptid
suggest
role
regul
receptor
recruit
thrombin
platelet
plasma
membran
facilit
stimul
par
jone
et
al
found
mediat
internalis
platelet
dual
aktglycogen
synthas
mechan
studi
look
express
pattern
platelet
identifi
express
level
variabl
within
human
popul
approxim
copi
estim
present
cell
surfac
analysi
relationship
receptor
express
level
platelet
respons
platelet
agonist
reveal
invers
relationship
level
express
platelet
respons
stimul
crp
adp
jone
et
al
although
associ
describ
modest
account
total
variabl
respons
similar
level
magnitud
observ
posit
correl
gpvi
express
level
platelet
respons
despit
overal
neg
role
regul
platelet
activ
signal
cell
type
associ
regul
integrin
function
wherebi
crosslink
enhanc
adhes
mediat
integrin
tanaka
et
al
piali
et
al
leavesley
et
al
berman
et
al
varon
et
al
chiba
et
al
zhao
newman
studi
human
platelet
shown
antibodi
crosslink
enhanc
adhes
spread
fibrinogen
zhao
newman
indic
posit
role
regul
integrin
mous
platelet
defici
show
impair
spread
adhes
fibrinogen
clot
retract
phosphoryl
focal
adhes
kinas
suggest
defect
integrin
outsidein
signal
wee
jackson
hypothesis
dual
role
could
therefor
exist
initi
function
suppress
platelet
activ
platelet
strongli
activ
posit
regul
function
mediat
integrin
outsidein
signal
jone
et
al
high
plasma
cholesterol
level
significantli
increas
individu
risk
atherosclerosi
coronari
heart
diseas
heart
attack
stroke
statin
wide
prescrib
cholesterol
lower
drug
shown
reduc
platelet
activ
describ
one
possibl
mechan
statin
inhibit
platelet
function
activ
regul
mora
et
al
treatment
platelet
simvastatin
result
increas
phosphoryl
recruit
itim
essenti
neg
function
support
statin
work
defici
mous
platelet
show
reduc
sensit
statin
compar
wt
control
indic
statin
exert
effect
via
carcinoembryon
antigen
cea
relat
cell
adhes
molecul
itim
contain
membran
receptor
express
human
mous
platelet
contain
extracellular
glycosyl
igdomain
four
two
transmembran
domain
long
cytoplasm
tail
contain
itim
almost
ident
two
protein
salaheldeen
et
al
activ
follow
cluster
via
homophil
interact
endogen
ligand
yet
identifi
activ
murin
coronaviru
mous
hepat
viru
spike
glycoprotein
robitail
et
al
studi
use
cell
type
includ
tcell
epitheli
cell
nagaishi
et
al
shown
use
itim
recruit
lesser
degre
initi
neg
regul
posit
signal
pathway
beauchemin
et
al
mice
defici
either
show
increas
adhes
fibrillar
collagen
increas
aggreg
secret
evok
gpvi
indic
role
receptor
neg
regul
gpvi
signal
platelet
respons
wong
et
al
alshahrani
et
al
defici
platelet
also
shown
exhibit
increas
platelet
respons
agonist
rhodocytin
platelet
defici
either
show
increas
tyrosin
phosphoryl
syk
follow
stimul
crp
also
rhodocytin
platelet
platelet
mice
defici
either
display
increas
thrombu
growth
vitro
vivo
suggest
like
neg
regul
platelet
gpvi
signal
also
similar
observ
recent
describ
platelet
show
reduc
signal
activ
suggest
altern
posit
regulatori
mechan
platelet
yip
et
al
role
regul
integrin
yet
unknown
transmembran
protein
identifi
proteom
gene
express
studi
macaulay
et
al
seni
et
al
variant
confirm
present
platelet
seni
et
al
contain
extracellular
domain
consist
amino
acid
cytoplasm
tail
contain
two
itim
sequenc
endogen
ligand
yet
identifi
shown
constitut
phosphoryl
rest
platelet
increas
follow
stimul
gpvi
specif
agonist
crp
thrombin
seni
et
al
treatment
cell
express
pervanad
inhibit
phosphatas
enhanc
tyrosin
phosphoryl
recruit
de
vet
et
al
coxon
et
al
therebi
suggest
work
via
similar
mechan
itim
contain
protein
inhibit
platelet
interestingli
studi
use
cell
line
show
inhibit
gpvi
signal
follow
express
retain
absenc
also
retain
absenc
ship
suggest
redund
phosphatas
involv
inhibitori
molecul
mechan
action
mori
et
al
recent
studi
identifi
capabl
interact
sever
key
signal
molecul
includ
csk
src
fyn
syk
suggest
may
mediat
inhibitori
effect
signal
platelet
activ
redistribut
signal
molecul
away
substrat
coxon
et
al
evid
neg
regulatori
role
platelet
found
use
crosslink
antibodi
caus
inhibit
platelet
aggreg
crp
adp
alter
adpstimul
signal
observ
suggest
act
downstream
releas
suggest
may
act
via
altern
inhibitori
mechan
observ
downstream
itim
contain
receptor
pecam
ceacam
capabl
inhibit
signal
event
downstream
mobilis
intracellular
newland
et
al
howev
defici
mice
show
platelet
hyperreact
although
like
attribut
increas
gpvi
receptor
shed
observ
result
enhanc
metalloproteinas
product
megakaryocyt
mice
mazharian
et
al
indic
import
role
megakaryocyt
physiolog
role
platelet
remain
unclear
mazharian
et
al
leukocyt
immunoglobulin
like
receptor
lilr
includ
two
subfamili
lilra
lilrb
whilst
lilra
protein
contain
itam
domain
lilrb
famili
member
characteris
contain
itim
human
platelet
express
mous
platelet
express
homolog
pirb
contain
four
cytoplasm
itim
takai
platelet
also
found
express
pirb
ligand
found
alpha
granul
may
suggest
autocrin
selfneg
regul
platelet
via
follow
activ
may
occur
zheng
et
al
fan
et
al
recent
studi
identifi
treatment
platelet
purifi
result
inhibit
activ
sever
agonist
includ
crp
adp
thrombin
adhes
spread
fibrinogen
also
inhibit
fan
et
al
pirbtm
mutant
mice
unabl
mediat
intracellular
signal
receptor
hyperreact
platelet
phenotyp
increas
aggreg
evok
crp
increas
spread
fibrinogen
increas
clot
retract
key
gpvi
signal
event
follow
activ
crp
includ
phosphoryl
lat
inhibit
follow
treatment
increas
pirbtm
mutant
adhes
fibrinogen
phosphoryl
fak
also
enhanc
pirbtm
mous
platelet
pirb
depend
inhibit
gpvi
integrin
signal
link
recruit
phosphatas
recruit
pirb
phosphoryl
follow
treatment
recruit
phosphoryl
reduc
pirbtm
express
mice
fan
et
al
ppar
repres
three
nuclear
receptor
isoform
berri
et
al
involv
cell
develop
differenti
cholesterol
fatti
acid
metabol
glucos
homeostasi
brien
et
al
barak
et
al
kersten
et
al
three
isoform
ppar
upon
bind
ligand
capabl
heterodimeris
rxr
anoth
nuclear
receptor
identifi
acut
nongenom
neg
regulatori
effect
human
platelet
treatment
platelet
ligand
fenofibr
statin
found
increas
intracellular
level
camp
result
inhibit
adpstimul
platelet
activ
fenofibr
also
found
inhibit
platelet
activ
increas
bleed
time
wt
mice
mice
defici
ali
et
al
follow
activ
fenofibr
found
associ
key
posit
mediat
platelet
activ
thought
interact
may
part
contribut
neg
regul
platelet
activ
observ
follow
treatment
ligand
shown
decreas
plaqu
format
attenu
progress
atherosclerosi
lee
et
al
studi
use
synthet
agonist
identifi
inhibitori
action
ligand
mobilis
intracellular
platelet
aggreg
follow
stimul
adp
platelet
agonist
ali
et
al
key
inhibitori
mediat
platelet
function
also
ligand
inhibitori
effect
platelet
activ
could
mediat
forman
et
al
treatment
platelet
agonist
result
increas
camp
level
identifi
potenti
bind
partner
receptor
potenti
mechan
may
regul
platelet
reactiv
ali
et
al
agonist
thiazolidinedion
current
use
treatment
type
diabet
mellitu
observ
clinic
cardioprotect
properti
reduc
risk
myocardi
infarct
dormandi
et
al
sauer
et
al
emerg
role
agonist
neg
regul
platelet
function
may
provid
mechanist
basi
observ
clinic
studi
measur
platelet
function
patient
coronari
heart
diseas
treat
rosiglitazon
report
longterm
antiplatelet
effect
downregul
pselectin
exposur
granul
secret
treat
patient
sidhu
et
al
treatment
platelet
ex
vivo
endogen
agonist
synthet
agonist
rosiglitazon
result
reduc
platelet
respons
includ
granul
secret
thromboxan
synthesi
respons
thrombin
adp
akbiyik
et
al
agonist
also
shown
suppress
platelet
activ
stimul
gpvi
agonist
platelet
aggreg
granul
secret
mobilis
intracellular
inhibit
follow
treatment
mora
et
al
treatment
agonist
result
reduc
thrombu
format
vitro
vivo
mora
et
al
li
et
al
addit
statin
routin
prescrib
cholesterol
lower
drug
also
shown
activ
ppar
ali
et
al
treatment
human
whole
blood
statin
pravastatin
fluvastatin
simvastatin
result
reduct
platelet
aggreg
adp
decreas
platelet
activ
attribut
ppar
mediat
increas
camp
level
human
platelet
megakaryocyt
express
mora
et
al
treatment
platelet
endogen
agonist
rxr
acid
synthet
agonist
methopren
acid
result
inhibit
gq
protein
coupl
induc
platelet
aggreg
stimul
adp
thromboxan
thought
rxr
regul
gpcr
mediat
platelet
activ
bind
gq
liganddepend
manner
inhibit
gq
induc
rac
activ
intracellular
releas
mora
et
al
isoform
lxr
implic
regul
fatti
acid
cholesterol
glucos
homeostasi
viennoi
et
al
agonist
lxr
describ
antiinflammatori
effect
atheroprotect
joseph
et
al
tangirala
et
al
identifi
isoform
present
platelet
spyridon
et
al
endogen
ligand
lxr
receptor
includ
oxysterol
oxygen
deriv
cholesterol
sever
synthet
agonist
includ
also
exist
gabbi
et
al
et
al
treatment
platelet
synthet
agonist
result
inhibit
platelet
activ
includ
aggreg
secret
integrin
activ
stimul
collagen
crp
thrombin
mice
form
smaller
less
stabl
thrombi
follow
laser
injuri
cremast
arteriol
lxr
also
shown
interact
sever
compon
gpvi
signal
pathway
follow
treatment
includ
syk
result
decreas
phosphoryl
signal
spyridon
et
al
mora
et
al
glucocorticoid
receptor
gr
activ
glucocorticoid
steroid
hormon
major
class
antiinflammatori
hormon
prednisolon
synthet
deriv
cortisol
use
understand
role
gr
regul
platelet
function
platelet
preincub
prednisolon
prior
agonist
stimul
show
reduc
aggreg
releas
respons
adp
mimet
could
revers
follow
treatment
gr
antagonist
mifepriston
mora
et
al
howev
mechan
underli
neg
regul
platelet
function
gr
agonist
still
poorli
understood
recent
identifi
import
inhibitor
integrin
activ
stefanini
et
al
regul
critic
regul
integrin
function
platelet
chrzanowskawodnicka
et
al
stefanini
et
al
posit
regul
guanin
exchang
factor
gef
crittenden
et
al
provid
oppos
neg
regul
maintain
platelet
quiescent
state
rest
stefanini
et
al
defici
embryon
lethal
mice
homozyg
express
mutat
form
impair
activ
result
viabl
anim
platelet
hyperreact
rescu
simultan
defici
howev
integrin
activ
doubl
knockout
mous
occur
independ
adp
receptor
jama
transmembran
protein
ctx
famili
express
cell
surfac
identifi
platelet
mice
defici
jama
display
increas
aggreg
sever
platelet
agonist
increas
spread
fibrinogen
clot
retract
increas
thrombu
format
indic
role
jama
neg
regul
integrin
naik
et
al
jama
phosphoryl
rest
platelet
associ
naik
et
al
jama
propos
keep
integrin
inact
bind
ctermin
src
kinas
csk
via
domain
recruit
integrin
recruit
csk
ensur
csrc
associ
integrin
remain
inact
state
phosphoryl
inhibitori
csrc
regulatori
domain
naik
et
al
platelet
activ
jama
dephosphoryl
csk
dissoci
enabl
activ
csrc
integrin
activ
studi
use
apo
defici
mice
model
high
plasma
cholesterol
level
atherosclerosi
highlight
import
platelet
inhibitori
receptor
jama
develop
diseas
state
recent
studi
shown
platelet
defici
inhibitori
receptor
jama
mice
fed
high
fat
diet
increas
aortic
plaqu
format
recruit
inflammatori
cell
suggest
platelet
hyperreact
observ
platelet
contribut
atherosclerot
plaqu
format
karshovska
et
al
esam
transmembran
glycoprotein
like
jama
member
ctx
famili
also
suggest
involv
neg
regul
adhes
integrin
outsidein
signal
contrast
jama
esam
appear
neg
regul
integrin
limit
activ
follow
platelet
activ
esam
contain
platelet
alpha
granul
transloc
cell
surfac
activ
nasdala
et
al
mous
platelet
defici
esam
show
increas
aggreg
gpcr
agonist
inhibit
clot
retract
increas
thrombu
format
vivo
reduc
tail
bleed
stalker
et
al
mechan
esam
function
current
unknown
although
interact
via
pdz
domain
scaffold
protein
highlight
possibl
interact
regul
sever
protein
includ
gpcr
hall
et
al
g
protein
rochdi
et
al
compon
cytoskeleton
shenolikar
et
al
glycoprotein
releas
endotheli
cell
goodwin
et
al
also
trap
stimul
platelet
enabl
platelet
selfregul
limit
activ
steel
et
al
treatment
platelet
result
inhibit
platelet
adhes
shape
chang
reduc
dens
granul
secret
reduc
rhoa
activ
lead
diminish
integrin
activ
aggreg
platelet
thought
exert
effect
activ
canon
signal
pathway
compon
also
appear
present
platelet
semenov
et
al
macdonald
et
al
huang
cell
type
shown
play
role
regul
cell
adhes
involv
support
interact
cadherin
cytoskeleton
huang
neg
regul
platelet
activ
via
signal
thought
occur
regul
small
gtpase
activ
includ
rhoa
steel
et
al
thought
favour
gdpbound
state
rho
via
regul
rhoa
gtpase
activ
whilst
increas
level
gtp
level
inhibit
integrin
adhes
spread
semaphorin
exist
solubl
coval
bound
homodim
secret
vascular
endotheli
cell
serini
et
al
semaphorin
neg
regul
platelet
function
bind
receptor
complex
identifi
platelet
takahashi
et
al
tamagnon
et
al
kashiwagi
et
al
semaphorin
treatment
inhibit
platelet
function
possibl
regul
integrin
activ
integrin
aggreg
adhes
spread
evok
sever
platelet
agonist
impair
exact
mechan
semaphorin
inhibit
platelet
function
fulli
elucid
although
inhibit
gtpase
appear
key
regulatori
step
neg
regul
cytoskelet
rearrang
kashiwagi
et
al
bind
activ
prostaglandin
receptor
platelet
surfac
duttaroy
sinha
propag
inhibitori
signal
activ
gs
subunit
activ
adenylyl
cyclas
stimul
product
camp
atp
gorman
et
al
camp
activ
camp
depend
protein
kinas
pka
follow
platelet
activ
agonist
adp
thrombin
adenylyl
cyclas
activ
inhibit
camp
level
reduc
gi
signal
jantzen
et
al
yang
et
al
pka
phosphoryl
multipl
target
protein
maintain
platelet
inact
rest
state
limit
platelet
activ
sever
substrat
pka
well
characteris
link
neg
regul
platelet
includ
vasp
involv
cytoskelet
rearrang
waldmann
et
al
butt
et
al
inhibit
key
regul
integrin
affin
schultess
et
al
miura
et
al
inositol
trisphosph
receptor
involv
regul
cavallini
et
al
thromboxan
receptor
reid
kinsella
target
also
includ
manganello
et
al
wardel
et
al
caldaggefi
schultess
et
al
recent
studi
identifi
camp
independ
mechan
pka
activ
follow
stimul
platelet
thrombin
collagen
gambaryan
et
al
rest
platelet
popul
platelet
pka
appear
associ
follow
stimul
collagen
thrombin
catalyt
subunit
pka
dissoci
activ
enabl
phosphoryl
activ
substrat
identifi
inhibitori
feedback
mechan
prevent
excess
platelet
activ
respons
stimuli
gambaryan
et
al
cyclic
nucleotid
cgmp
key
neg
regul
platelet
activ
inhibit
platelet
keep
rest
state
healthi
vasculatur
smolenski
endotheli
releas
nitric
oxid
keep
platelet
inact
regul
intracellular
level
cgmp
mellion
et
al
radomski
et
al
follow
synthesi
releas
healthi
endothelium
cross
platelet
plasma
membran
bind
activ
solubl
guanyl
cyclas
sgc
lead
increas
product
cgmp
gtp
activ
protein
kinas
g
pkg
level
cgmp
control
phosphodiesteras
present
platelet
haslam
et
al
platelet
defici
pkg
insensit
cgmpmediat
inhibit
intracellular
releas
eigenthal
et
al
pkg
knockout
mice
prothrombot
phenotyp
exhibit
increas
intravascular
adhes
aggreg
follow
ischaemia
massberg
et
al
platelet
also
consid
sourc
mechan
platelet
synthesis
whether
physiolog
import
howev
still
area
content
although
establish
neg
regul
platelet
function
vascular
endothelium
tradit
consid
domin
sourc
within
blood
vessel
platelet
report
express
two
nitric
oxid
synthas
no
isoform
ino
eno
gener
less
endotheli
cell
radomski
et
al
presenc
eno
contenti
gambaryan
et
al
studi
effect
plateletderiv
platelet
function
use
inoseno
knockout
mice
suggest
eno
major
regul
platelet
function
gambaryan
et
al
tymvio
et
al
evid
platelet
produc
nitrat
although
research
need
understand
mechan
apostoli
et
al
platelet
product
induc
mediat
elev
radomski
et
al
therefor
stimul
mani
platelet
agonist
adp
arachidon
acid
howev
question
whether
plateletderiv
inhibit
platelet
aggreg
sourc
debat
gkaliagkousi
et
al
report
describ
plateletderiv
nomedi
inhibit
radomski
et
al
b
other
report
effect
thoma
et
al
thompson
et
al
recent
studi
provid
evid
presenc
function
eno
platelet
measur
product
singl
platelet
flow
cozzi
et
al
also
highlight
antithrombot
potenti
drug
modul
platelet
eno
activ
momi
et
al
defect
campcgmp
signal
pathway
potenti
contribut
platelet
hyperreact
cardiovascular
diseas
includ
ischem
heart
diseas
heart
failur
diabet
reduc
sensit
platelet
inhibitori
effect
contribut
platelet
hyperreact
chirkov
horowitz
platelet
patient
type
diabet
mellitu
insulin
insensit
exampl
reduc
sensit
prostacyclin
consequ
higher
platelet
reactiv
addit
number
individu
genet
abnorm
prostacyclin
signal
reduc
camp
level
result
hyperreact
platelet
prothrombot
state
defect
sgc
function
link
increas
preval
ischem
heart
diseas
heart
failur
diabet
van
geet
et
al
contrast
patient
hypersensit
prostacyclin
signal
result
increas
activ
gs
protein
show
increas
risk
bleed
attribut
increas
camp
level
increas
inhibit
platelet
function
van
geet
et
al
also
suggest
patient
obes
addit
defect
sgc
function
camp
synthesi
may
also
alter
defect
downstream
effector
camp
cgmp
signal
may
contribut
platelet
hyperreact
russo
et
al
protein
modif
phosphoryl
key
mechan
signal
transduct
platelet
phosphoryl
revers
posttransl
modif
enabl
regul
signal
transduct
platelet
function
phosphatas
depend
dephosphoryl
key
signal
protein
phosphatas
key
mediat
sever
neg
signal
pathway
platelet
exhibit
itim
contain
receptor
protein
tyrosin
phosphatas
pten
wellestablish
role
neg
regul
platelet
signal
gener
neg
regul
receptor
proxim
signal
event
lead
reduc
mobilis
granul
secret
integrin
activ
seni
wellestablish
role
neg
regul
platelet
signal
event
downstream
major
platelet
agonist
includ
gpvi
gpcr
et
al
jackson
et
al
observ
support
studi
use
mous
platelet
defici
show
enhanc
activ
fibrinogen
mazharian
et
al
histidin
phosphatas
dephosphoryl
inactiv
syk
prevent
downstream
signal
thoma
et
al
defici
mice
platelet
show
increas
hyperreact
gpvi
agonist
also
increas
thrombu
format
reduc
bleed
time
phosphoinositid
phosphatas
pten
involv
regul
function
alter
phosphoinositol
cycl
laurent
et
al
ptendefici
platelet
show
hyperrespons
collagen
exhibit
increas
activ
show
reduc
bleed
time
vivo
final
serinethreonin
kinas
phosphatas
involv
neg
regul
integrin
function
signal
pradhan
et
al
gushiken
et
al
mediat
dephosphoryl
reduc
src
phosphoryl
activ
mayanglambam
et
al
pradhan
et
al
gushiken
et
al
import
note
howev
whilst
sever
phosphatas
associ
neg
regul
platelet
function
mani
posit
regulatori
function
phosphatas
identifi
platelet
seni
platelet
regul
limit
respons
platelet
agonist
desensitis
receptor
follow
agonist
stimul
adp
exampl
critic
secondari
mediat
platelet
signal
yet
despit
shown
platelet
desensitis
follow
continu
exposur
adp
mundel
et
al
hardi
et
al
cunningham
et
al
diminish
respons
attribut
desensitis
receptor
via
agonist
mediat
internalis
receptor
studi
use
platelet
cell
identifi
receptor
desensitis
differ
mechan
follow
platelet
agonist
stimul
desensitis
receptor
mediat
classic
novel
isoform
protein
kinas
c
pkc
whilst
desensitis
mediat
g
protein
coupl
receptor
kinas
novel
isoform
pkc
hardi
et
al
protein
kinas
c
pkc
famili
serinethreonin
kinas
regul
mani
aspect
platelet
signal
differ
isoform
pkc
classifi
three
differ
subtyp
classic
novel
atyp
isoform
accord
structur
mechan
regul
sever
isoform
identifi
human
platelet
although
express
isoform
controversi
newton
mellor
parker
murugappan
et
al
buensuceso
et
al
hall
et
al
pear
et
al
konopatskaya
et
al
bynagari
et
al
nagi
et
al
harper
pool
histor
pkc
famili
consid
play
overal
posit
role
regul
platelet
activ
broad
spectrum
pkc
inhibitor
shown
inhibit
granul
secret
synthesi
integrin
activ
aggreg
thrombu
format
harper
pool
howev
neg
regulatori
role
subsequ
also
identifi
pkc
famili
studi
use
broad
spectrum
inhibitor
also
identifi
neg
role
regul
receptor
desensitis
see
section
receptor
desensitis
releas
studi
use
isoform
specif
defici
mice
identifi
neg
regulatori
role
novel
isoform
harper
pool
transgen
mice
defici
identifi
neg
regulatori
role
regul
integrin
outsidein
signal
filopodia
format
fibrinogen
due
interact
vasp
pula
et
al
also
shown
neg
regul
gpviinduc
platelet
respons
platelet
defici
mice
enhanc
aggreg
dens
granul
secret
comparison
wt
control
also
confirm
human
platelet
use
cell
permeabl
peptid
design
block
interact
tat
chari
et
al
contrast
report
howev
also
exist
group
found
abnorm
gpvidepend
dens
granul
secret
platelet
pula
et
al
defici
platelet
gener
larger
thrombi
measur
vitro
measur
vivo
gilio
et
al
chari
et
al
overal
role
therefor
difficult
defin
possibl
consequ
divers
posit
neg
regulatori
role
play
pkc
isoform
studi
utilis
isoformspecif
inhibitor
identifi
neg
role
sever
process
gpviinduc
platelet
activ
includ
aggreg
secret
activ
chang
intracellular
level
increas
follow
treatment
platelet
inhibitor
studi
utilis
defici
mice
gener
conflict
report
posit
neg
role
regul
platelet
activ
hall
et
al
nagi
et
al
harper
pool
cohen
et
al
unsworth
et
al
gilio
et
al
differ
attribut
differ
experiment
condit
wherebi
may
neg
role
follow
exposur
low
agonist
concentr
posit
role
follow
exposur
higher
concentr
platelet
agonist
hall
et
al
nagi
et
al
cohen
et
al
platelet
activ
trigger
stimuli
aris
within
circulationactiv
platelet
initi
posit
feedback
mechan
support
thrombu
growthplatelet
also
gener
neg
feedback
signal
limit
thrombu
developmentth
mechan
neg
regul
divers
mani
yet
fulli
characterisedneg
regulatori
mechan
may
import
posit
regul
understand
diseas
risk
discov
new
drug
target
therapi
